{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:22:31Z","timestamp":1791246151038,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1038\/nrrheum.2011.62","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T13:48:03Z","timestamp":1307108883000},"page":"360-368","source":"Crossref","is-referenced-by-count":71,"title":["Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma"],"prefix":"10.1038","volume":"7","author":[{"given":"Catarina","family":"Dias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Isenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,3]]},"reference":[{"key":"BFnrrheum201162_CR1","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1182\/blood-2008-07-077982","volume":"112","author":"ES Jaffe","year":"2008","unstructured":"Jaffe, E. S., Harris, N. L., Stein, H. & Isaacson, P. G. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 112, 4384\u20134399 (2008).","journal-title":"Blood"},{"key":"BFnrrheum201162_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/00313020500370192","volume":"37","author":"AE Grulich","year":"2005","unstructured":"Grulich, A. E. & Vajdic, C. M. The epidemiology of non-Hodgkin lymphoma. Pathology 37, 409\u2013419 (2005).","journal-title":"Pathology"},{"key":"BFnrrheum201162_CR3","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/ijc.24141","volume":"124","author":"LR Goldin","year":"2009","unstructured":"Goldin, L. R. & Landgren, O. Autoimmunity and lymphomagenesis. Int. J. Cancer 124, 1497\u20131502 (2009).","journal-title":"Int. J. Cancer"},{"key":"BFnrrheum201162_CR4","first-page":"1408","volume-title":"Cecil Medicine","author":"PJ Bierman","year":"2007","unstructured":"Bierman, P. J., Harris, N. & Armitage, J. O. in Cecil Medicine 23rd edn 1408\u20131420 (Saunders Elsevier, Philadelphia, 2007)."},{"key":"BFnrrheum201162_CR5","first-page":"687","volume-title":"Harrison's Principles of Internal Medicine","author":"DL Longo","year":"2008","unstructured":"Longo, D. L. in Harrison's Principles of Internal Medicine 17th edn 687\u2013688 (McGraw-Hill Medical, New York, 2008)."},{"key":"BFnrrheum201162_CR6","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","volume":"165","author":"E Zintzaras","year":"2005","unstructured":"Zintzaras, E., Voulgarelis, M. & Moutsopoulos, H. M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch. Intern. Med. 165, 2337\u20132344 (2005).","journal-title":"Arch. Intern. Med."},{"issue":"Suppl.","key":"BFnrrheum201162_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijc.22719","volume":"120","author":"DD Alexander","year":"2007","unstructured":"Alexander, D. D.  et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int. J. Cancer 120 (Suppl.), 1\u201339 (2007).","journal-title":"Int. J. Cancer"},{"key":"BFnrrheum201162_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.autrev.2009.07.004","volume":"9","author":"E Kiss","year":"2010","unstructured":"Kiss, E., Kovacs, L. & Szodoray, P. Malignancies in systemic lupus erythematosus. Autoimmun. Rev. 9, 195\u2013199 (2010).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201162_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/ncprheum0620","volume":"3","author":"A Hansen","year":"2007","unstructured":"Hansen, A., Lipsky, P. E. & D\u00f6rner, T. B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat. Clin. Pract. Rheumatol. 3, 561\u2013569 (2007).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"BFnrrheum201162_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/art.21675","volume":"54","author":"E Baecklund","year":"2006","unstructured":"Baecklund, E.  et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 54, 692\u2013701 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201162_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/jnci\/djj004","volume":"98","author":"KE Smedby","year":"2006","unstructured":"Smedby, K. E.  et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J. Natl Cancer Inst. 98, 51\u201360 (2006).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrrheum201162_CR12","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","volume":"111","author":"KE Smedby","year":"2008","unstructured":"Smedby, K. E.  et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111, 4029\u20134038 (2008).","journal-title":"Blood"},{"key":"BFnrrheum201162_CR13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/art.23267","volume":"58","author":"L Mellemkjaer","year":"2008","unstructured":"Mellemkjaer, L.  et al. Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum. 58, 657\u2013666 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201162_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/ijc.24287","volume":"125","author":"LA Anderson","year":"2009","unstructured":"Anderson, L. A.  et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int. J. Cancer 125, 398\u2013405 (2009).","journal-title":"Int. J. Cancer"},{"key":"BFnrrheum201162_CR15","doi-asserted-by":"crossref","unstructured":"Ansell, P.  et al. Non-Hodgkin lymphoma and autoimmunity: does gender matter? Int J Cancer. doi: 10.1002\/ijc.25680.","DOI":"10.1002\/ijc.25680"},{"key":"BFnrrheum201162_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal, A.  et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225\u2013249 (2009).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrrheum201162_CR17","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/j.1365-2141.2009.08010.x","volume":"148","author":"A Smith","year":"2010","unstructured":"Smith, A.  et al. The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br. J. Haematol. 148, 739\u2013753 (2010).","journal-title":"Br. J. Haematol."},{"key":"BFnrrheum201162_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/jnci\/djq043","volume":"102","author":"SY Kristinsson","year":"2010","unstructured":"Kristinsson, S. Y.  et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstr\u00f6m macroglobulinemia. J. Natl Cancer Inst. 102, 557\u2013567 (2010).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrrheum201162_CR19","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/art.21029","volume":"52","author":"S Bernatsky","year":"2005","unstructured":"Bernatsky, S.  et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 52, 1481\u20131490 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201162_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.autrev.2009.04.001","volume":"9","author":"A Tincani","year":"2010","unstructured":"Tincani, A., Taraborelli, M. & Cattaneo, R. Antiphospholipid antibodies and malignancies. Autoimmun. Rev. 9, 200\u2013202 (2010).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201162_CR21","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/art.27402","volume":"62","author":"K Hellgren","year":"2010","unstructured":"Hellgren, K., Smedby, K. E., Feltelius, N., Baecklund, E. & Askling, J. Do rheumatoid arthritis and lymphoma share risk factors? A comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis. Arthritis Rheum. 62, 1252\u20131258 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201162_CR22","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/rheumatology\/kei281","volume":"45","author":"MN Lazarus","year":"2006","unstructured":"Lazarus, M. N., Robinson, D., Mak, V., Moller, H. & Isenberg, D. A. Incidence of cancer in a cohort of patients with primary Sj\u00f6gren's syndrome. Rheumatology 45, 1012\u20131015 (2006).","journal-title":"Rheumatology"},{"key":"BFnrrheum201162_CR23","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/ard.2005.035311","volume":"64","author":"P Geborek","year":"2005","unstructured":"Geborek, P.  et al. Tumor necrosis factor do not increase overall risk in patient with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann. Rheum. Dis. 64, 657\u2013658 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201162_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.autrev.2006.02.007","volume":"5","author":"S De Vita","year":"2006","unstructured":"De Vita, S. & Quartuccio, L. Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun. Rev. 5, 443\u2013448 (2006).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201162_CR25","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1136\/ard.2009.117762","volume":"69","author":"X Mariette","year":"2010","unstructured":"Mariette, X.  et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann. Rheum. Dis. 69, 400\u2013408 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201162_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/pds.2046","volume":"20","author":"J Askling","year":"2011","unstructured":"Askling, J.  et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol. Drug Saf. 20, 119\u2013130 (2011).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"BFnrrheum201162_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.autrev.2009.07.002","volume":"9","author":"L Kov\u00e1cs","year":"2010","unstructured":"Kov\u00e1cs, L., Szodoray, P. & Kiss, E. Secondary tumours in Sj\u00f6gren's Syndrome. Autoimmun. Rev. 9, 203\u2013206 (2010).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201162_CR28","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3324\/haematol.2009.005983","volume":"94","author":"RJ Bende","year":"2009","unstructured":"Bende, R. J., van Maldegem, F. & van Noesel, C. J. Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas. Haematologica 94, 1109\u20131123 (2009).","journal-title":"Haematologica"},{"key":"BFnrrheum201162_CR29","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3324\/haematol.2009.008979","volume":"94","author":"SY Kristinsson","year":"2009","unstructured":"Kristinsson, S. Y.  et al. Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica 94, 1581\u20131589 (2009).","journal-title":"Haematologica"},{"key":"BFnrrheum201162_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cell.2007.06.033","volume":"130","author":"CC Goodnow","year":"2007","unstructured":"Goodnow, C. C. Multistep pathogenesis of autoimmune disease. Cell 130, 25\u201335 (2007).","journal-title":"Cell"},{"key":"BFnrrheum201162_CR31","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/0961203308092164","volume":"17","author":"P Youinou","year":"2008","unstructured":"Youinou, P. Is BAFF the murderer in lupus? Lupus 17, 613\u2013614 (2008).","journal-title":"Lupus"},{"key":"BFnrrheum201162_CR32","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.smim.2006.04.004","volume":"18","author":"SG Tangye","year":"2006","unstructured":"Tangye, S. G., Bryant, V. L., Cuss, A. K. & Good, K. L. BAFF, APRIL and human B cell disorders. Semin. Immunol. 18, 305\u2013317 (2006).","journal-title":"Semin. Immunol."},{"key":"BFnrrheum201162_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(00)02481-8","volume":"356","author":"C Cellier","year":"2000","unstructured":"Cellier, C.  et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 356, 203\u2013208 (2000).","journal-title":"Lancet"},{"key":"BFnrrheum201162_CR34","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1182\/blood-2005-09-3679","volume":"107","author":"F Suarez","year":"2006","unstructured":"Suarez, F., Lortholary, O., Hermine, O. & Lecuit, M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 107, 3034\u20133044 (2006).","journal-title":"Blood"},{"key":"BFnrrheum201162_CR35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.berh.2008.12.007","volume":"23","author":"S Bernatsky","year":"2009","unstructured":"Bernatsky, S., Ramsey-Goldman, R. & Clarke, A. E. Malignancy in systemic lupus erythematosus: what have we learned? Best Pract. Res. Clin. Rheumatol. 23, 539\u2013547 (2009).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"BFnrrheum201162_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/art.22476","volume":"57","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals, M.  et al. Characterization of B cell lymphoma in patients with Sjogren's syndrome and hepatitis C virus infection. Arthritis Rheum 57, 161\u2013170 (2007).","journal-title":"Arthritis Rheum"},{"key":"BFnrrheum201162_CR37","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/jcp.2007.047977","volume":"84","author":"G Brady","year":"2008","unstructured":"Brady, G., Macarthur, G. J. & Farrell, P. J. Epstein\u2013Barr virus and Burkitt lymphoma. Postgrad. Med. J. 84, 372\u2013377 (2008).","journal-title":"Postgrad. Med. J."},{"key":"BFnrrheum201162_CR38","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1258\/095646203321605585","volume":"14","author":"L Calza","year":"2003","unstructured":"Calza, L.  et al. Systemic and discoid lupus erythematosus in HIV-infected patients treated with highly active antiretroviral therapy. Int. J. STD AIDS 14, 356\u2013359 (2003).","journal-title":"Int. J. STD AIDS"},{"key":"BFnrrheum201162_CR39","first-page":"1175","volume":"134","author":"SLI Reyes","year":"2006","unstructured":"Reyes, S. L. I.  et al. BAFF: a regulatory cytokine of B lymphocytes involved in autoimmunity and lymphoid cancer [Spanish]. Rev. Med. Chil. 134, 1175\u20131184 (2006).","journal-title":"Rev. Med. Chil."},{"key":"BFnrrheum201162_CR40","doi-asserted-by":"publisher","first-page":"5042","DOI":"10.1158\/0008-5472.CAN-06-4752","volume":"67","author":"SS Wang","year":"2007","unstructured":"Wang, S. S.  et al. Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res. 67, 5042\u20135054 (2007).","journal-title":"Cancer Res."},{"key":"BFnrrheum201162_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/sj.gene.6364055","volume":"5","author":"JP Bayley","year":"2004","unstructured":"Bayley, J. P., Ottenhoff, T. H. & Verweij, C. L. Is there a future for TNF promoter polymorphisms? Genes Immun. 5, 315\u2013329 (2004).","journal-title":"Genes Immun."},{"key":"BFnrrheum201162_CR42","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.4049\/jimmunol.166.6.3915","volume":"166","author":"AW Gibson","year":"2001","unstructured":"Gibson, A. W.  et al. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J. Immunol. 166, 3915\u20133922 (2001).","journal-title":"J. Immunol."},{"key":"BFnrrheum201162_CR43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/431405a","volume":"431","author":"F Balkwill","year":"2004","unstructured":"Balkwill, F. & Coussens, L. M. Cancer: an inflammatory link. Nature 431, 405\u2013406 (2004).","journal-title":"Nature"},{"key":"BFnrrheum201162_CR44","doi-asserted-by":"publisher","first-page":"9771","DOI":"10.1158\/0008-5472.CAN-06-0324","volume":"66","author":"SS Wang","year":"2006","unstructured":"Wang, S. S.  et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res. 66, 9771\u20139780 (2006).","journal-title":"Cancer Res."},{"key":"BFnrrheum201162_CR45","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1182\/blood-2010-07-295097","volume":"117","author":"Y Chen","year":"2011","unstructured":"Chen, Y.  et al. Cytokine polymorphisms in Th1\/Th2 pathway genes, body mass index and risk of non-Hodgkin lymphoma. Blood 117, 585\u2013589 (2011).","journal-title":"Blood"},{"key":"BFnrrheum201162_CR46","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1517\/14656566.8.13.2089","volume":"8","author":"E Toussirot","year":"2007","unstructured":"Toussirot, E. & Wendling, D. The use of TNF-\u03b1 blocking agents in rheumatoid arthritis: an update. Expert Opin. Pharmacother. 8, 2089\u20132107 (2007).","journal-title":"Expert Opin. Pharmacother."},{"key":"BFnrrheum201162_CR47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/ard.2006.069039","volume":"67","author":"S Bernatsky","year":"2008","unstructured":"Bernatsky, S.  et al. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case\u2013cohort study. Ann. Rheum. Dis. 67, 74\u201379 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201162_CR48","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1517\/14712598.7.9.1287","volume":"7","author":"T D\u00f6rner","year":"2007","unstructured":"D\u00f6rner, T. & Lipsky, P. E. B-cell targeting: a novel approach to immune intervention today and tomorrow. Expert Opin. Biol. Ther. 7, 1287\u20131299 (2007).","journal-title":"Expert Opin. Biol. Ther."},{"key":"BFnrrheum201162_CR49","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.autrev.2009.08.007","volume":"9","author":"T D\u00f6rner","year":"2009","unstructured":"D\u00f6rner, T.  et al. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun. Rev. 9, 82\u201389 (2009).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201162_CR50","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.pharmthera.2010.01.001","volume":"125","author":"T D\u00f6rner","year":"2010","unstructured":"D\u00f6rner, T., Kinnman, N. & Tak, P. P. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol. Ther. 125, 464\u2013475 (2010).","journal-title":"Pharmacol. Ther."},{"key":"BFnrrheum201162_CR51","doi-asserted-by":"publisher","first-page":"424935","DOI":"10.1155\/2009\/424935","volume":"2009","author":"L Quartuccio","year":"2009","unstructured":"Quartuccio, L.  et al. Controversies on rituximab therapy in Sj\u00f6gren syndrome-associated lymphoproliferation. Int. J. Rheumatol. 2009, 424935 (2009).","journal-title":"Int. J. Rheumatol."},{"issue":"Suppl.","key":"BFnrrheum201162_CR52","first-page":"S133","volume":"52","author":"JC Edwards","year":"2005","unstructured":"Edwards, J. C., Leandro, M. J. & Cambridge, G. Repeated B lymphocyte depletion therapy in rheumatoid arthritis: 5 year follow-up. Arthritis Rheum. 52 (Suppl.), S133\u2013S134 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201162_CR53","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/rheumatology\/kel393","volume":"46","author":"C Popa","year":"2007","unstructured":"Popa, C., Leandro, M. J., Cambridge, G. & Edwards, J. C. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 46, 626\u2013630 (2007).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201162_CR54","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.3748\/wjg.v16.i44.5543","volume":"16","author":"T Watanabe","year":"2010","unstructured":"Watanabe, T. Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development. World J. Gastroenterol. 16, 5543\u20135554 (2010).","journal-title":"World J. Gastroenterol."},{"key":"BFnrrheum201162_CR55","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/ard.2005.046193","volume":"65","author":"M Voulgarelis","year":"2006","unstructured":"Voulgarelis, M., Giannouli, S., Tzioufas, A. G. & Moutsopoulos, H. M. Long term remission of Sj\u00f6gren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann. Rheum. Dis. 65, 1033\u20131037 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201162_CR56","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/rheumatology\/keh248","volume":"43","author":"M Voulgarelis","year":"2004","unstructured":"Voulgarelis, M., Giannouli, S., Anagnostou, D. & Tzioufas, A. G. Combined therapy with rituximab plus cyclophosphamide\/doxorubicin\/vincristine\/prednisone (CHOP) for Sj\u00f6gren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology (Oxford) 43, 1050\u20131053 (2004).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201162_CR57","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/art.21260","volume":"52","author":"J Pijpe","year":"2005","unstructured":"Pijpe, J.  et al. Rituximab treatment in patients with primary Sj\u00f6gren's syndrome: an open-label phase II study. Arthritis Rheum. 52, 2740\u20132750 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201162_CR58","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrrheum.2009.218","volume":"5","author":"C Favas","year":"2009","unstructured":"Favas, C. & Isenberg, D. A. B-cell depletion therapy in SLE\u2014what are the current prospects for its acceptance? Nat. Rev. Rheumatol. 5, 711\u2013716 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum201162_CR59","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1200\/JCO.2008.19.9117","volume":"27","author":"F Morschhauser","year":"2009","unstructured":"Morschhauser, F.  et al. Humanized anti-CD20 antibody, veltuzumab, in refractory\/recurrent non-Hodgkin's lymphoma: phase I\/II results. J. Clin. Oncol. 27, 3346\u20133353 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201162_CR60","first-page":"200","volume":"11","author":"C Milani","year":"2009","unstructured":"Milani, C. & Castillo, J. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr. Opin. Mol. Ther. 11, 200\u2013207 (2009).","journal-title":"Curr. Opin. Mol. Ther."},{"key":"BFnrrheum201162_CR61","doi-asserted-by":"publisher","first-page":"R129","DOI":"10.1186\/ar2018","volume":"8","author":"SD Steinfeld","year":"2006","unstructured":"Steinfeld, S. D.  et al. Epratuzumab (humanized anti-CD22 antibody) in primary Sj\u00f6gren's syndrome: an open-label phase I\/II study. Arthritis Res. Ther. 8, R129 (2006).","journal-title":"Arthritis Res. Ther."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2011.62.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2011.62","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2011.62.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:29:29Z","timestamp":1684470569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2011.62"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["BFnrrheum201162"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2011.62","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}